Sir, Legionella spp., particularly Legionella pneumophila, are an important cause of community-acquired pneumonia. 1 Standard treatment involves intracellularly active agents, supported by in vitro and clinical outcome data. 1 Legionella spp. are fastidious, requiring charcoal-containing culture media, buffered charcoal yeast extract (BCYE), which binds inhibitory substances and facilitates growth. 1 However, charcoal also binds antimicrobials, 2, 3 and attempts to remove charcoal from media yield poor growth. 3 Despite this, MICs have been determined using BCYE by broth dilution, agar dilution and Etest methods, [2] [3] [4] with the Etest method comparable to other methods. 4 In New Zealand, Legionella longbeachae predominates, 5 and our centre has a large collection of clinical isolates following the introduction of mandatory testing of all respiratory samples of patients with suspected pneumonia. 6 We sought to define WT susceptibilities to commonly used antimicrobials [azithromycin (Sigma PHR1088), clarithromycin (Sigma PHR1038), ciprofloxacin (Sigma 17850), moxifloxacin (Bayer), rifampicin (Sigma R3501) and tetracycline (Sigma T-3383)] using our archived isolates. We established broth dilution MIC ranges and compared them with those obtained using the Etest method.
Sixty-one archived L. longbeachae clinical isolates cultured from respiratory samples of patients admitted to Christchurch Hospital, Christchurch, New Zealand between 2005 and 2014 were studied. Isolates were confirmed as L. longbeachae by standard phenotypic testing and MALDI-TOF MS analysis and were subcultured twice on BCYE media supplemented with a-ketoglutarate at 35 C. Colonies were suspended in sterile saline to a turbidity equivalent to that of a 0.5 McFarland standard. Broth dilutions were performed as recommended by CLSI M100-S22 7 using 2-fold serial dilutions of the antibiotics in buffered yeast extract (BYE) broth. The broth dilution MIC plates were incubated at 35 C in ambient air and inhibitory concentrations were determined at 72 h. Etests were performed by the inoculation of the organism (turbidity equivalent to that of a 0.5 McFarland standard) on to BCYE plates (Fort Richard Laboratories, Auckland, New Zealand). Etest gradient strips (AB Biodisk) were applied for azithromycin, clarithromycin, ciprofloxacin, moxifloxacin, rifampicin and tetracycline. Plates were incubated at 35 C and read at 48 h. Etest strips were read by eyepiece according to the manufacturer's instructions.
MIC 50 and MIC 90 values and ranges after 48 h of incubation are shown in Table 1 for both Etest-and broth dilution-derived MICs.
To evaluate the potential effect of charcoal-binding antimicrobials, susceptibilities of the ATCC strain 29213 of Staphylococcus aureus were determined using both Mueller-Hinton and BCYE media, using the same methodology and antimicrobials. MIC values fell within the CLSI range on Mueller-Hinton agar, but MIC values were markedly elevated on BCYE media for all antimicrobials. Rifampicin was most affected, with nine dilutions difference between the MICs on the different agars.
To the best of our knowledge, this is the first study determining the antimicrobial susceptibility patterns of clinical L. longbeachae isolates. All antimicrobials tested except for tetracycline had low MICs, with the lowest MIC 90 (0.031 mg/L) of ciprofloxacin, rifampicin and moxifloxacin by broth dilution. Broth dilution-derived MICs were lower than Etest values, particularly for the quinolones, with seven dilutions difference between their MIC 90 values. Compared with the other antimicrobials, tetracycline had markedly elevated MIC 90 values by broth dilution and Etest (64 and 32 mg/L). This may be due to poor diffusion of tetracycline into the media or variations in electrolyte content of the media leading to chelation of tetracycline. Additionally, tetracycline reductase enzymes have been identified in soil-derived L. longbeachae specimens, which have been shown to inactivate tetracycline in vivo, but as yet have not been identified in L. pneumophila. Our results are similar to MICs for L. pneumophila determined by the same methodology 4, 9 (Table 1) , with higher Etest-derived MIC 90 values of rifampicin (0.38 versus 0.032 mg/L) and tetracycline (32 versus 8 mg/L). The reason for this difference is unclear and may represent a genuine difference in susceptibility between the two Legionella species.
A major limitation is the effect of charcoal-binding antimicrobials as illustrated by the S. aureus control and the lower broth dilution-derived MIC values using BYE. The effect of charcoal binding has previously been explored; reducing the charcoal concentration of BCYE by 75% yielded 4-8-fold lower MIC 90 values of ciprofloxacin and gemifloxacin, although levofloxacin, erythromycin and clarithromycin MIC values were unaffected. 2 The difference in MIC persisted in comparison with BYE media, confirming the difference in MIC is due to charcoal-binding free drug. Despite this, non-L. pneumophila species have been found to grow poorly on charcoal-free media 3 and adequate growth is necessary for accurate MIC derivation. Accordingly, EUCAST recommend BCYE for L. pneumophila susceptibility testing. 10 These findings may not translate to in vivo efficacy and more data are needed to define further the WT susceptibilities. However, they support use of the Etest method on BCYE media for MIC derivation and reinforce the use of quinolones in clinical disease. Our results are derived from clinical isolates in one geographical area of New Zealand only and may not be representative of isolates in other regions or environmental isolates. 1 has created an urgent need to identify effective therapeutic options that can treat serious infections caused by these XDR bacteria. Ceftazidime/avibactam has been successfully used to treat infection caused by carbapenemresistant Enterobacteriaceae; 2, 3 however, the combination lacks activity against strains producing NDM. These carbapenemases remain susceptible to aztreonam, although most MBL-producing isolates also harbour ESBLs or other b-lactamases that confer resistance to aztreonam. 4 The combination of aztreonam and avibactam has demonstrated potent in vitro activity against MBLproducing Enterobacteriaceae including those isolates that also carry other b-lactamases.
5 However, this combination is currently in clinical development and unavailable for clinical use.
In our hospital, we experienced an outbreak of Klebsiella pneumoniae ST147 in late 2015 caused by an XDR strain producing NDM-1 ! OXA-48 ! CTX-M-15 (KP-HUB-ST147). 6 Herein, we retrospectively review the outcomes of 10 patients treated with ceftazidime/avibactam plus aztreonam between January 2016 and June 2017 at Bellvitge University Hospital, Barcelona, Spain. All patients were attended by an infectious diseases physician after informing the patient about the need for using the combination therapy and obtaining oral consent. As ceftazidime/avibactam was still not approved by the Spanish Medicines Agency, this antibiotic was obtained on a compassionate basis. This study had the approval of the local Ethics Committee (reference: EPA033/17). Clinical success was defined as survival and the absence of recurrence at day 30 after the onset of the infection, with resolution of the signs and symptoms of infection, and sterilization of site-specific cultures within 7 days of starting combination therapy. 7 To check for longterm recurrence, patients were followed up for 90 days after the onset of infection. Recurrence was defined as a new positive culture with the reappearance of clinical signs and symptoms of infection after clinical success.
The MICs of antibiotics were determined via microdilution, using a commercial NC53 panel by the MicroScan system (Beckman Coulter, Inc.) and a DKMGN panel by the Sensititre TM system (TREK Diagnostic Systems Ltd). The synergistic activity of ceftazidime/avibactam and aztreonam was tested in vitro, using disc diffusion [ceftazidime/avibactam (30/20 lg) and aztreonam (30 lg)]. All isolates showed synergistic activity. MIC clinical breakpoints were defined according to EUCAST. 8 Ten patients received ceftazidime/avibactam and aztreonam; five of them (50%) were receiving immunosuppressant therapy (three were liver recipients, one was a kidney recipient and one was receiving long-term corticosteroid therapy). In total, five (50%) infections were bacteraemic (four were secondary and one was primary). All infections were caused by a KP-HUB-ST147, which was resistant to b-lactam antibiotics, including aztreonam (MIC .32 mg/L), ceftazidime/avibactam (MIC .16/4 mg/L), meropenem (MIC .16 mg/L), imipenem (MIC .16 mg/L), aminoglycosides, fluoroquinolones and trimethoprim/sulfamethoxazole, and only showed intermediate susceptibility to tigecycline (MIC " 2 mg/L). In four patients, the strain was resistant to colistin (MIC .8 mg/L). Clinical success was achieved in 6 of the 10 patients (60%). Failures were due to death (n " 3) and recurrence (n " 1). Two of the six patients with clinical success (33.3%) had a recurrence within 90 days, but these were patients with structural anomalies at the site of infection. One infection was a bacteraemic 
